Required dose of sugammadex or neostigmine for reversal of vecuronium‐induced shallow residual neuro...
Required dose of sugammadex or neostigmine for reversal of vecuronium‐induced shallow residual neuromuscular block at a train‐of‐four ratio of 0.3
About this item
Full title
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Residual shallow neuromuscular block (NMB) is potentially harmful and contributes to critical respiratory events. Evidence for the optimal dose of sugammadex required to reverse vecuronium‐induced shallow NMB is scarce. The aims of the present study were to find suitable doses of sugammadex and neostigmine to reverse a residual vecuronium‐induced N...
Alternative Titles
Full title
Required dose of sugammadex or neostigmine for reversal of vecuronium‐induced shallow residual neuromuscular block at a train‐of‐four ratio of 0.3
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_68c71d79a34a48f2b1104a4fd80ebbd6
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_68c71d79a34a48f2b1104a4fd80ebbd6
Other Identifiers
ISSN
1752-8054
E-ISSN
1752-8062
DOI
10.1111/cts.13143
